/
NXL
$4.90-$0.20 (-3.91%)prev close
Change$-62.60
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.1M
1M shares
52-week range
$4.51 – $60.00
1% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
15.9
Nexalin Technology, Inc. Common Stock
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
www.nexalin.com- Employees
- 8
- IPO / List date
- Sep 16, 2022
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds NXL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 10,676 | $3.7K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-08-31 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded NXL yet.
